Estimation of medroxyprogesterone acetate (MPA) and etoposide against a human uterine endometrial cancer
Ishizaki, T.; Yamamoto, T.; Itoh, R.; Yasuda, J.; Fujita, H.; Okada, H.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(14): 2521-2523
1994
ISSN/ISBN: 0385-0684 PMID: 7944503 Document Number: 429340
Document emailed within 1 workday
Related Documents
Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D. 1986: Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients Anticancer Research 6(3 Part A): 362Karimi-Zarchi, M.; Dehghani-Firoozabadi, R.; Tabatabaie, A.; Dehghani-Firoozabadi, Z.; Teimoori, S.; Chiti, Z.; Miratashi-Yazdi, A.; Dehghani, A. 2013: A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation Clinical and Experimental Obstetrics and Gynecology 40(3): 421-424
Sica, G.; Iacopino, F.; Marini, L.; Robustelli della Cuna, G. 1992: Antiproliferative effect of leuprorelin acetate, alone or combined with tamoxifen or medroxyprogesterone acetate, on human breast cancer cell lines Clinical Therapeutics 14 Suppl A: 87-96
1991: Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives International Journal of Cancer 49(2): 186-190
1991: Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives International Journal of Cancer 49(2): 186-190
1991: Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives International Journal of Cancer 49(2): 186-190
Kim, M.K.; Seong, S.J.; Kim, Y.S.; Song, T.; Kim, M.-L.; Yoon, B.S.; Jun, H.S.; Lee, Y.H. 2013: Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer American Journal of Obstetrics and Gynecology 209(4): 358.E1-4
Zia, Y.; Tang, J.H.; Chinula, L.; Tegha, G.; Stanczyk, F.Z.; Kourtis, A.P. 2019: Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi Contraception 100(5): 402-405
Mantovani, G.; Macciò, A.; Lai, P.; Massa, E.; Ghiani, M.; Santona, M.C. 1998: Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate Seminars in Oncology 25(2 Suppl 6: 45-52
Sereepapong, W.; Chotnopparatpattara, P.; Taneepanichskul, S.; Markham, R.; Russell, P.; Fraser, I.S. 2004: Endometrial progesterone and estrogen receptors and bleeding disturbances in depot medroxyprogesterone acetate users Human Reproduction 19(3): 547-552
Bruckner, H.W.; Deppe, G. 1977: Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate Obstetrics and Gynecology 50(1 Suppl): 10s-12s
Tomasicchio, M.; Avenant, C.; Du Toit, A.; Ray, R.M.; Hapgood, J.P. 2013: The progestin-only contraceptive medroxyprogesterone acetate, but not norethisterone acetate, enhances HIV-1 Vpr-mediated apoptosis in human CD4+ T cells through the glucocorticoid receptor PLOS one 8(5): E62895
Riippa, P.; Kauppila, A.; Sundström, H.; Vihko, R. 1984: Hepatic impairment during simultaneous administration of medroxyprogesterone acetate and tamoxifen in the treatment of endometrial and ovarian carcinoma Anticancer Research 4(3): 109-112
Piver, M.S.; Barlow, J.J.; Lurain, J.R.; Blumenson, L.E. 1980: Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma Cancer 45(2): 268-272
Goshtasebi, A.; Moukhah, S.; Gandevani, S.B. 2013: Treatment of heavy menstrual bleeding of endometrial origin: randomized controlled trial of medroxyprogesterone acetate and tranexamic acid Archives of Gynecology and Obstetrics 288(5): 1055-1060
Tabatabaie, A.; Karimi Zarchi, M.; Dehghani-Tafti, M.; Miratashi-Yazdi, A.; Teimoori, S.; Dehghani, A. 2013: Comparing letrozole with medroxyprogesterone acetate (MPA) as hormonal therapy for simple endometrial hyperplasia without atypia in adult and middle-aged women European Journal of Gynaecological Oncology 34(6): 552-555
Blümel, J.E.; Roncagliolo, M.E.; Gramegna, G.; Vásquez, R.; Estartus, A.; Tacla, X.; Brandt, A. 1994: Double-blind method of the effect of menopause symptoms, lipid profile, and endometrial thickness of continuous therapy with estradiol valerate and medroxyprogesterone acetate Revista Chilena de Obstetricia y Ginecologia 59(5): 354-360
Telimaa, S.; Kauppila, A.; Rönnberg, L.; Suikkari, A.M.; Seppälä, M. 1989: Elevated serum levels of endometrial secretory protein PP14 in patients with advanced endometriosis. Suppression by treatment with danazol and high-dose medroxyprogesterone acetate American Journal of Obstetrics and Gynecology 161(4): 866-871
Thomas, D.B.; Ray, R.M. 1995: Depot-medroxyprogesterone acetate (DMPA) and risk of invasive adenocarcinomas and adenosquamous carcinomas of the uterine cervix. WHO Collaborative Study of Neoplasia and Steroid Contraceptives Contraception 52(5): 307-312
Lumbiganon, P. 1994: Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary Contraception 49(3): 203-209